Clinical Research Studies

If you have been diagnosed with advanced cutaneous Squamous cell Carcinoma (CSCC), you may qualify to participate in a study evaluating the clinical benefit of an investigational drug, REGN2810.  The main goal of this phase II trial is to find out whether the drug REGN2810 stops your cancer from growing, evaluate how well you tolerate this drug, and determine the amount of drug levels in your body over time, which is known as pharmacokinetic (PK) testing.  This study will also evaluate how your disease and the study drug have affected your view on life and lastly evaluate the relationship between biomarkers (proteins) of interest.